Flexion Therapeutics Inc (OQ:FLXN)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 10 Mall Rd Ste 301
BURLINGTON MA 01803-4121
Tel: N/A
Website: flexiontherapeutics.com
IR: See website
Key People
Patrick J. Mahaffy
Independent Chairman of the Board
Michael D. Clayman
President, Chief Executive Officer, Director
David A. Arkowitz
Chief Financial Officer
Neil Bodick
Chief Scientific Officer
Mark Levine
General Counsel and Corporate Secretary
Scott D. Kelley
Chief Medical Officer
Kerry Wentworth
Chief Regulatory Officer
Christina Willwerth
Chief Strategy Officer
Business Overview
Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
Financial Overview
For the nine months ended 30 September 2019, Flexion Therapeutics Inc revenues increased from $13M to $49.3M. Net loss decreased 10% to $116.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other income increase of 9% to $394K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$3.42 to -$3.06.
Employees: 272 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $625.55M as of Sep 30, 2019
Annual revenue (TTM): $58.85M as of Sep 30, 2019
EBITDA (TTM): -$142.74M as of Sep 30, 2019
Net annual income (TTM): -$156.83M as of Sep 30, 2019
Free cash flow (TTM): -$153.76M as of Sep 30, 2019
Net Debt Last Fiscal Year: $15.51M as of Sep 30, 2019
Shares outstanding: 38,174,760 as of Nov 1, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization